EA201690388A1 - Новые производные унциаламицина, способы их синтеза и их применение в качестве противоопухолевых агентов - Google Patents
Новые производные унциаламицина, способы их синтеза и их применение в качестве противоопухолевых агентовInfo
- Publication number
- EA201690388A1 EA201690388A1 EA201690388A EA201690388A EA201690388A1 EA 201690388 A1 EA201690388 A1 EA 201690388A1 EA 201690388 A EA201690388 A EA 201690388A EA 201690388 A EA201690388 A EA 201690388A EA 201690388 A1 EA201690388 A1 EA 201690388A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- uncialamicine
- synthesis
- methods
- application
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
В одном аспекте настоящее изобретение относится к новым аналогам унциаламицина. Настоящее изобретение также относится к новым путям синтеза для получения унциаламицина и его аналогов. Кроме того, в настоящем изобретении также описаны способы применения унциаламицина и его аналогов. В другом аспекте настоящее изобретение относится к конъюгатам антитела с лекарственным средством, которые могут быть использованы для лечения рака или другого заболевания или нарушения.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361865896P | 2013-08-14 | 2013-08-14 | |
US201361868783P | 2013-08-22 | 2013-08-22 | |
US201461937003P | 2014-02-07 | 2014-02-07 | |
PCT/US2014/051127 WO2015023879A1 (en) | 2013-08-14 | 2014-08-14 | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201690388A1 true EA201690388A1 (ru) | 2016-07-29 |
Family
ID=51453866
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201690388A EA201690388A1 (ru) | 2013-08-14 | 2014-08-14 | Новые производные унциаламицина, способы их синтеза и их применение в качестве противоопухолевых агентов |
Country Status (13)
Country | Link |
---|---|
US (3) | US9777013B2 (ru) |
EP (1) | EP3033346B1 (ru) |
JP (2) | JP6474404B2 (ru) |
KR (1) | KR20160068738A (ru) |
CN (1) | CN105899515B (ru) |
AU (2) | AU2014306592B2 (ru) |
CA (1) | CA2921401A1 (ru) |
EA (1) | EA201690388A1 (ru) |
ES (1) | ES2769876T3 (ru) |
IL (1) | IL244084B (ru) |
MX (2) | MX368016B (ru) |
SG (2) | SG10201810067YA (ru) |
WO (1) | WO2015023879A1 (ru) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6474404B2 (ja) * | 2013-08-14 | 2019-02-27 | ウィリアム マーシュ ライス ユニバーシティWilliam Marsh Rice University | ウンシアラマイシン誘導体、合成方法、および抗腫瘍薬としてのそれらの使用 |
EP3079668A1 (en) | 2013-12-09 | 2016-10-19 | Durect Corporation | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same |
EP3733698A1 (en) | 2015-09-23 | 2020-11-04 | Bristol-Myers Squibb Company | Glypican-3 binding fibronectin based scafflold molecules |
EP3394096A1 (en) | 2015-12-21 | 2018-10-31 | Bristol-Myers Squibb Company | Variant antibodies for site-specific conjugation |
WO2018048975A1 (en) | 2016-09-09 | 2018-03-15 | Bristol-Myers Squibb Company | Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment |
EA202092747A1 (ru) | 2018-05-29 | 2021-03-16 | Бристол-Маерс Сквибб Компани | Модифицированные саморазрушающиеся фрагменты для применения в пролекарствах и конъюгатах и способы применения и изготовления |
SI3886914T1 (sl) | 2018-11-30 | 2023-06-30 | Bristol-Myers Squibb Company | Protitelo, ki vsebuje C-terminalni podaljšek lahke verige, ki vsebuje glutamin, njegove konjugate ter metode in uporabe |
US20220031860A1 (en) | 2018-12-12 | 2022-02-03 | Bristol-Myers Squibb Company | Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses |
CN109928981B (zh) * | 2019-04-19 | 2021-06-11 | 长沙天赐生物医药科技有限公司 | 洋浦霉素类似物、制备方法及其应用 |
WO2021055306A1 (en) | 2019-09-16 | 2021-03-25 | Bristol-Myers Squibb Company | Dual capture method for analysis of antibody-drug conjugates |
US11027253B2 (en) | 2019-09-26 | 2021-06-08 | Chevron Phillips Chemical Company Lp | Systems and methods for reducing heat exchanger fouling rate |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
EP0537229A1 (en) * | 1990-07-05 | 1993-04-21 | Akzo Nobel N.V. | Receptor directed-toxin conjugates |
US5281710A (en) | 1990-08-01 | 1994-01-25 | The Scripps Research Institute | Dynemicin analogs: synthesis, methods of preparation and use |
US5162330A (en) | 1990-11-05 | 1992-11-10 | Bristol-Myers Squibb Co. | Dynemicin c antibiotic, its triacetyl derivative and pharmaceutical composition containing same |
JP2985435B2 (ja) | 1990-11-05 | 1999-11-29 | ロンザ リミテッド | 3−アミノクロトンニトリルの製造方法 |
US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
WO1996003124A1 (en) * | 1994-07-27 | 1996-02-08 | California Institute Of Technology | Dynemicin analogs |
GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
US5739169A (en) | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
US6232287B1 (en) | 1998-03-13 | 2001-05-15 | The Burnham Institute | Molecules that home to various selected organs or tissues |
US6528481B1 (en) | 1999-02-16 | 2003-03-04 | The Burnam Institute | NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods |
EP2829609A1 (en) | 1999-08-24 | 2015-01-28 | E. R. Squibb & Sons, L.L.C. | Human CTLA-4 antibodies and their uses |
US7452964B2 (en) | 2001-09-07 | 2008-11-18 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides against placenta and adipose tissues |
US7183388B2 (en) | 2001-03-30 | 2007-02-27 | The Regents Of The University Of California | Anti-MUC-1 single chain antibodies for tumor targeting |
US20060223114A1 (en) | 2001-04-26 | 2006-10-05 | Avidia Research Institute | Protein scaffolds and uses thereof |
US8507445B2 (en) | 2001-09-07 | 2013-08-13 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
US7671010B2 (en) | 2002-08-30 | 2010-03-02 | The Board Of Regents Of The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
AU2001298053A1 (en) | 2001-09-27 | 2003-04-14 | Pieris Proteolab Ag | Muteins of apolipoprotein D |
WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
BR0306808A (pt) | 2002-01-09 | 2005-08-30 | Medarex Inc | Anticorpos monoclonais humanos contra cd30 |
WO2003104418A2 (en) | 2002-06-06 | 2003-12-18 | Research Corporation Technologies, Inc. | Reconstituted polypeptides |
JP4680902B2 (ja) | 2003-07-22 | 2011-05-11 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | Rg1抗体及びその使用 |
WO2005051976A2 (en) | 2003-11-20 | 2005-06-09 | Ansata Therapeutics, Inc. | Protein and peptide ligation processes and one-step purification processes |
EP1747021B1 (en) | 2004-05-19 | 2015-09-09 | E. R. Squibb & Sons, L.L.C. | Self-immolative linkers and drug conjugates |
AU2005307789A1 (en) | 2004-11-16 | 2006-05-26 | Avidia Research Institute | Protein scaffolds and uses thereof |
WO2006056464A2 (en) | 2004-11-26 | 2006-06-01 | Pieris Ag | Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4) |
MX2007009935A (es) | 2005-02-18 | 2007-10-10 | Medarex Inc | Anticuerpos monoclonales que carecen de residuos fucosilo contra antigeno membranal especifico de prostata (psma). |
AU2006214031A1 (en) | 2005-02-18 | 2006-08-24 | Medarex, Inc. | Human monoclonal antibodies to prostate specific membrane antigen (PSMA) |
LT2439273T (lt) | 2005-05-09 | 2019-05-10 | Ono Pharmaceutical Co., Ltd. | Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais |
CA2611814A1 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
EP1934261B1 (en) | 2005-09-26 | 2014-10-29 | Medarex, L.L.C. | Human monoclonal antibodies to cd70 |
WO2007038868A2 (en) * | 2005-10-03 | 2007-04-12 | The University Of British Columbia | Novel enediyne compound and uses thereof |
DK1957539T3 (da) | 2005-12-08 | 2013-05-06 | Medarex Inc | Humane monoklonale antistoffer til proteintyrosinkinase 7 (ptk7) og deres anvendelse |
BRPI0620601A2 (pt) | 2005-12-08 | 2011-11-16 | Medarex Inc | anticorpo monoclonal humano isolado ou uma porção ligante ao antìgeno do mesmo, composição, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para preparar um anticorpo anti-o8e e método para tratar ou prevenir uma doença definida pelo crescimento de células tumorais expressando o8e |
EP2338898A1 (en) | 2006-03-09 | 2011-06-29 | The Board of Regents of the University of Texas System | Compositions and methods related to profiling a plurality of cell lines based on peptide binding |
AR060978A1 (es) | 2006-05-30 | 2008-07-23 | Genentech Inc | Anticuerpos e inmunoconjugados y sus usos |
JP5620100B2 (ja) | 2006-06-29 | 2014-11-05 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 非天然アミノ酸を含有するタンパク質の無細胞合成の方法 |
EP2064316B1 (en) | 2006-09-08 | 2012-01-25 | Ambrx, Inc. | Site specific incorporation of non-natural amino acids by vertebrate cells |
MX2009005776A (es) | 2006-12-01 | 2009-06-10 | Medarex Inc | Anticuerpos humanos que se enlazan al cd 22 y sus usos. |
WO2008074004A2 (en) | 2006-12-14 | 2008-06-19 | Medarex, Inc. | Human antibodies that bind cd70 and uses thereof |
UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
JP5868593B2 (ja) | 2007-07-17 | 2016-02-24 | メダレックス・リミテッド・ライアビリティ・カンパニーMedarex, L.L.C. | Glypican−3に対するモノクローナル抗体 |
CN101951946B (zh) | 2007-10-01 | 2014-12-10 | 百时美施贵宝公司 | 结合间皮素的人抗体及其应用 |
ATE555200T1 (de) | 2008-02-05 | 2012-05-15 | Medical Res Council | Verfahren und zusammensetzungen |
US8450278B2 (en) | 2008-10-15 | 2013-05-28 | Board Of Regents, The University Of Texas System | MUC18 targeting peptides |
WO2010087994A2 (en) | 2009-01-30 | 2010-08-05 | Whitehead Institute For Biomedical Research | Methods for ligation and uses thereof |
MX350539B (es) | 2012-02-13 | 2017-09-08 | Bristol Myers Squibb Co | Compuestos de enediino, conjugados de los mismos y sus usos y metodos. |
US8798431B2 (en) | 2012-06-01 | 2014-08-05 | Telefonaktiebolaget L M Ericsson (Publ) | Fine-grained optical shuffle interconnect topology migration |
JP6474404B2 (ja) | 2013-08-14 | 2019-02-27 | ウィリアム マーシュ ライス ユニバーシティWilliam Marsh Rice University | ウンシアラマイシン誘導体、合成方法、および抗腫瘍薬としてのそれらの使用 |
-
2014
- 2014-08-14 JP JP2016534843A patent/JP6474404B2/ja active Active
- 2014-08-14 CA CA2921401A patent/CA2921401A1/en not_active Abandoned
- 2014-08-14 WO PCT/US2014/051127 patent/WO2015023879A1/en active Application Filing
- 2014-08-14 US US14/911,881 patent/US9777013B2/en active Active
- 2014-08-14 MX MX2016001975A patent/MX368016B/es active IP Right Grant
- 2014-08-14 AU AU2014306592A patent/AU2014306592B2/en not_active Ceased
- 2014-08-14 KR KR1020167006599A patent/KR20160068738A/ko not_active Application Discontinuation
- 2014-08-14 EA EA201690388A patent/EA201690388A1/ru unknown
- 2014-08-14 EP EP14758223.3A patent/EP3033346B1/en active Active
- 2014-08-14 SG SG10201810067YA patent/SG10201810067YA/en unknown
- 2014-08-14 ES ES14758223T patent/ES2769876T3/es active Active
- 2014-08-14 CN CN201480056718.0A patent/CN105899515B/zh active Active
- 2014-08-14 SG SG11201601047SA patent/SG11201601047SA/en unknown
-
2016
- 2016-02-11 IL IL244084A patent/IL244084B/en not_active IP Right Cessation
- 2016-02-12 MX MX2019010875A patent/MX2019010875A/es unknown
-
2017
- 2017-08-15 US US15/677,959 patent/US10233192B2/en active Active
-
2019
- 2019-01-29 JP JP2019013008A patent/JP2019089804A/ja active Pending
- 2019-03-18 US US16/357,109 patent/US10889590B2/en active Active
- 2019-06-07 AU AU2019204034A patent/AU2019204034A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MX2016001975A (es) | 2016-11-14 |
AU2014306592A1 (en) | 2016-03-10 |
MX2019010875A (es) | 2019-12-19 |
JP6474404B2 (ja) | 2019-02-27 |
AU2019204034A1 (en) | 2019-07-04 |
JP2019089804A (ja) | 2019-06-13 |
IL244084A0 (en) | 2016-04-21 |
US20160185791A1 (en) | 2016-06-30 |
US20180065976A1 (en) | 2018-03-08 |
WO2015023879A1 (en) | 2015-02-19 |
MX368016B (es) | 2019-09-13 |
ES2769876T3 (es) | 2020-06-29 |
US10889590B2 (en) | 2021-01-12 |
KR20160068738A (ko) | 2016-06-15 |
CN105899515A (zh) | 2016-08-24 |
CN105899515B (zh) | 2020-01-14 |
CA2921401A1 (en) | 2015-02-19 |
JP2016534105A (ja) | 2016-11-04 |
AU2014306592B2 (en) | 2019-04-04 |
EP3033346A1 (en) | 2016-06-22 |
US10233192B2 (en) | 2019-03-19 |
US20190382412A1 (en) | 2019-12-19 |
US9777013B2 (en) | 2017-10-03 |
IL244084B (en) | 2019-08-29 |
SG11201601047SA (en) | 2016-03-30 |
EP3033346B1 (en) | 2020-01-08 |
SG10201810067YA (en) | 2018-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201690388A1 (ru) | Новые производные унциаламицина, способы их синтеза и их применение в качестве противоопухолевых агентов | |
CY1121076T1 (el) | Τρικυκλικες ενωσεις ως αντικαρκινικοι παραγοντες | |
EA201890530A1 (ru) | Конъюгаты антитела к dll3 и лекарственного средства и способы их применения | |
CY1123953T1 (el) | Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης | |
EA201690667A1 (ru) | Композиции, содержащие антитело к pdl1 | |
CY1119058T1 (el) | Ενωσεις ιμιδαζοπυρρολιδινονης | |
CL2016000468A1 (es) | Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso. | |
CU20160101A7 (es) | Inmunoglobulina con fab en tándem | |
EA201591524A1 (ru) | Производные 2-аминопиримидина для лечения вирусных инфекций | |
EA201691059A1 (ru) | Соединения-пептидомиметики и содержащие их конъюгаты антитело-лекарственное средство | |
EA201491811A1 (ru) | АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ | |
UY35399A (es) | Conjugados de fármacos con anticuerpos | |
EA201690633A1 (ru) | Способы и композиции, включающие комбинацию антагониста vegf и анти-ctla-4 антитела | |
EA201401077A1 (ru) | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения | |
MX361218B (es) | Análogos de spliceostatina. | |
CY1122483T1 (el) | Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης | |
EA201591740A1 (ru) | Вирусы болезни ньюкасла и их применение | |
EA201590174A1 (ru) | Иммуноконъюгаты, содержащие анти-cd22 антитела | |
EA201390472A1 (ru) | Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты | |
EA201591887A1 (ru) | Макроциклические деазаоксипурины для лечения вирусных инфекций | |
BR112015021521A2 (pt) | anticorpos anti-crth2 e métodos para seu uso | |
EA201591728A1 (ru) | Гетероциклические соединения и способы их применения | |
EA201892802A1 (ru) | Производные аденозина для применения при лечении рака | |
EA201892769A3 (ru) | Сложные диэфиры ациклических нуклеозидфосфонатов | |
EA201500383A1 (ru) | Производные 1,2,4-триазина для лечения вирусных инфекций |